

## Press Release

22 January 2024

---

### CESSATECH ANNOUNCES THAT MANAGEMENT AND BOARD HAVE EXERCISED ALL THEIR WARRANTS OF SERIES TO2

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES.

**Copenhagen, Denmark, January 22, 2024 – Cessatech A/S ("Cessatech" or the "Company") announces that all members of the Company's Senior Management and Board of Directors, including CEO Jes Trygved and Chairman of the Board of Directors, Martin Olin, have exercised all their warrants of Series TO2. In totality, Cessatech's Senior Management and Board of Directors will subscribe for approximately DKK 1.75 million through the exercise of their TO2 warrants.**

If all the warrants of series TO2 are exercised, the Company will receive approximately DKK 18.1 million before issuing costs. For the warrants to not expire without value, it is required that the holder actively subscribes for new shares no later than January 26, 2024 or sell the warrants no later than January 24, 2024. Please observe that certain nominees might close their applications earlier than January 26, 2024.

#### Summarised terms for the warrants of series TO2

Exercise period:	January 12, 2024 – January 26, 2024.
Issue size:	3,838,110 warrants of series TO2, which entitles to subscription of 3,838,110 shares. If all the warrants are exercised, the Company will receive approximately DKK 18.1 million before issuing costs.
Exercise price:	DKK 4.71 per share.
Last day trading warrants:	January 24, 2024.
Dilution:	If all warrants of series TO2 are exercised the share capital will increase with DKK 767,622 from DKK 2,757,751 to DKK 3,525,373. The dilution at the exercise of all warrants of series TO2 amounts to approximately 21.8 percent of the number of shares and number of votes.

Note that the warrants of series TO2 that are not exercised on January 26, 2024 at the latest or sold on January 24, 2024 at the latest, will expire without value. For the warrants of series TO2 not to expire without compensation, the holder must actively subscribe for new shares or sell the warrants of series TO2.

#### How warrants are exercised

- Nominee-registered warrants (Custody account) - Subscription and payment by the exercise of warrants of series TO2 shall be made in accordance with instructions from each nominee. Please contact your nominee for additional information. This should be done well before January 26, 2024, as different nominees have different processing times.
- Directly-registered warrants (Securities account) - No issue report nor any instructions regarding payments will be sent out. Subscriptions will be made through simultaneous payment in accordance with the instructions on the application form found on the Company's website.

The warrants of series T02 will then be replaced by interim shares awaiting registration at the Danish Business Authority.

### **Advisors**

Translution Capital acts as financial advisors to the Company in connection with the warrant exercise. Nordic Issuing is the Company's issuing agent whereas Elmann Law Firm is the Company's legal advisor in connection with the warrant exercise of series T02.

For more information about Cessatech, please contact:

Jes Trygved, CEO

Phone: +45 9387 2309

E-mail: [jes.trygved@cessatech.com](mailto:jes.trygved@cessatech.com)

[www.cessatech.com](http://www.cessatech.com)

*This press release constitutes inside information that Cessatech A/S is obliged to make public pursuant to the EU Market Abuse Regulation 596/2014. The information was sent for publication, through the agency of the contact persons set out above, at the time stated by the Company's news distributor, Cision, at the publication of this press release.*

### **About Cessatech A/S**

Cessatech A/S is a Danish pharmaceutical company committed to developing and commercializing evidence-based and innovative medicines for children for the treatment of paediatric acute pain. Its lead asset (CT001) is an analgesic nasal spray for the treatment of acute and planned painful procedures in children. The advantages include needle-free administration, easy administration, a fast-acting therapeutic effect, and being medically approved for children. CT001 is at its pivotal stage of clinical development, and CT002 is at the early development phase.